Abstract 100P
Background
Colon cancer (CC) is one of the most common malignancies in the world. In this study, we investigated the involvement of a mitosis related chromosome condensation protein NCAPG in tumor progression, and in the prognosis of human CC.
Methods
The patient cohort in this study consisted of 123 CC cases from 2009 to 2013, documenting pathologic and clinical factors, as well as clinical outcomes. Immunohistochemistry and immunoblotting were employed to examine the NCAPG expression in 123 pairs of normal and CC tissues and 7 colon cells. Based on the expression of NCAPG, one CC cell with high NCAPG level was chosen for knockdown of NCAPG expression. The effect of NCAPG knockdown on the growth, migration and invasion of NCAPG-manipulated CC cells was examined.
Results
NCAPG protein overexpression was observed in 88 patients and was significantly correlated with depth of invasion, distant metastasis, staging, and poor disease-free and overall survival. Multivariate Cox regression analysis showed that NCAPG overexpression is an indenpendent prognostic marker for CC. Furthermore, NCAPG expression was elevated in several CC cells. In vitro experiments indicated that NCAPG knockdown inhibited CC cell growth, migration and invasion.
Conclusions
This study suggests that overexpression of NCAPG can be a useful marker for predicting the outcome of CC patients and that NCAPG targeting can represent a potential modality for treating CC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chi Mei Medical Center.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract